KAPA (Kairos Pharma) Tariff Resilience Score: 7/10 (As of Jul. 02, 2026)


KAPA Kairos Pharma Ltd KAPA
15 GF Score
Price $0.37
View Full Analysis

What is Kairos Pharma Tariff Resilience Score?

Kairos Pharma KAPA -4.07% 15 Tariff Resilience Score is 7 as of Jul. 02, 2026. GuruFocus rates KAPA with a GF Score™ of 15/100. Among 1,374 Biotechnology companies, Kairos Pharma ranks better than 90.39% on this metric.

Kairos Pharma has the Tariff Resilience Score of 7, which implies that the company might have Highly Resilient.

Kairos Pharma has Kairos Pharma benefits from industry-specific exemptions and a primarily domestic supply chain, reducing its tariff vulnerability. Its focus on pharmaceuticals provides additional resilience.

Tariff Resilience Score is a ranking system developed by GuruFocus to measure a company's exposure to international trade tariffs, rated on a scale from 0 to 10. It takes into account key factors such as global supply chain dependencies, manufacturing locations versus sales markets, import / export balance and percentage of revenue, and more.

The company's exposure to international trade tariffs based on these criteria:

1. Global supply chain dependencies
2. Manufacturing locations versus sales markets
3. Import/export balance and percentage of revenue
4. Historical impact from previous tariff changes
5. Available mitigation strategies (alternative suppliers, pricing power)
6. Industry-specific tariff exemptions or vulnerabilities

Based on the research, GuruFocus believes Kairos Pharma might have Highly Resilient.

Kairos Pharma  (AMEX:KAPA) Tariff Resilience Score Explanation

The Tariff Resilience Score ranges from 0 to 10, with 10 as the most resilient. GuruFocus divided Moat Score into following 3 categories:

Tariff Resilience Score Resilience Level
7 - 10Highly Resilient
4 - 6Average Resilient
0 - 3Highly Vulnerable

Kairos Pharma Tariff Resilience Score Related Terms

KAPA vs IMNN, HCWB, CURX: Tariff Resilience Score Comparison

For the Biotechnology subindustry, Kairos Pharma's Tariff Resilience Score, along with its competitors' market caps and Tariff Resilience Score data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Kairos Pharma Tariff Resilience Score vs Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Kairos Pharma's Tariff Resilience Score distribution charts can be found below:

* The bar in red indicates where Kairos Pharma's Tariff Resilience Score falls into.


KAPA
15GF Score
Kairos Pharma Ltd KAPA
Tariff Resilience Score is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis
What does a Tariff Resilience Score of 7 mean?
Kairos Pharma (KAPA) has a Tariff Resilience Score of 7 as of Jul. 02, 2026. Tariff Score is a ranking system developed by GuruFocus to measure a company's exposure to international trade tariffs, rated on a scale from 0 to 10. It takes into account key factors such as global supply chain dependencies, manufacturing locations versus sales markets, import / export balance and percentage of revenue, and more. According to the industry distribution chart, Kairos Pharma ranks #132 out of 1374 companies in the Biotechnology industry, placing it in the top 9.6%.
Is Kairos Pharma's Tariff Resilience Score too high?
Kairos Pharma's current Tariff Resilience Score is 7. The Biotechnology industry median Tariff Resilience Score is 4.00. Kairos Pharma's value of 7 is 75% above this industry median. Based on the distribution chart, Kairos Pharma ranks #132 out of 1374 companies in the Biotechnology industry, which is in the top quartile — a strong position relative to peers. Overall, Kairos Pharma has a GF Score™ of 15/100, reflecting its overall financial health beyond just this single metric.
How does Kairos Pharma's Tariff Resilience Score compare to IMNN and HCWB?
According to the Biotechnology industry distribution chart, Kairos Pharma ranks #132 out of 1374 companies for Tariff Resilience Score. This places Kairos Pharma in the top 10% of its industry — outperforming the majority of peers. The industry median Tariff Resilience Score is 4.00. Kairos Pharma's value of 7 is 75% above this benchmark. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Tariff Resilience Score for a Biotechnology company?
The median Tariff Resilience Score among Biotechnology companies is 4.00, based on 1,374 companies in the industry. Companies in the top quartile (top 25%) have a Tariff Resilience Score significantly above this median, while those in the bottom quartile fall well below. However, Tariff Resilience Score should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Kairos Pharma's current Tariff Resilience Score of 7 is 75% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Tariff Resilience Score mean?
A high Tariff Resilience Score can signal that a stock is expensive relative to its fundamentals. Tariff Score is a ranking system developed by GuruFocus to measure a company's exposure to international trade tariffs, rated on a scale from 0 to 10. It takes into account key factors such as global supply chain dependencies, manufacturing locations versus sales markets, import / export balance and percentage of revenue, and more. For the Biotechnology industry, the median Tariff Resilience Score is 4.00 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Kairos Pharma's current Tariff Resilience Score is 7. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Kairos Pharma stock overvalued right now?
Kairos Pharma (KAPA) has a current Tariff Resilience Score of 7. The current Tariff Resilience Score is 7 and 75% above the Biotechnology industry median of 4.00. Kairos Pharma's overall GF Score™ is 15/100. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Tariff Resilience Score calculated?
Tariff Resilience Score is calculated from a company's financial statements. For Kairos Pharma (KAPA), the current Tariff Resilience Score is 7 as of Jul. 02, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Kairos Pharma Business Description

Address 2355 Westwood Boulevard, No. 139, Los Angeles, CA, USA, 90064
Kairos Pharma Ltd is a clinical-stage biopharmaceutical company. The company is engaged in therapeutics for cancer patients that are designed to overcome key hurdles in immune suppression and drug resistance. These therapeutics include antibodies and small molecules for the treatment of prostate cancer, lung cancer, breast cancer, and glioblastoma. The product portfolio of the company consists of Pre-clinical or clinical-trial stage drug candidates, Therapeutic agents, and other technologies for treating diseases.
15GF Score

Get the complete analysis for KAPA

Tariff Resilience Score is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$0.37
Price